Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine will allow Neon to develop further treatment modalities including next-generation vaccines and T cell therapies targeting both personalized as well as shared neoantigens. Neon Therapeutics' lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute, and is already in multiple clinical trials.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/01/15 | $55,000,000 | Series A |
Access Industries Clal Biotechnology Industries Third Rock Ventures | undisclosed |
| 01/05/17 | $70,000,000 | Series B |
Access Industries Fidelity Management & Research Company Inbio Ventures Nextech Invest Partner Fund Management Third Rock Ventures Wellington Management Company | undisclosed |
